When Oregon voters passed Measure 109, something shifted in the American psychedelic landscape that we're still living with the consequences of. Psilocybin — the active compound in so-called magic mushrooms — became legal for therapeutic use, with the state itself overseeing how it would be grown, distributed, and administered. No doctor's note required. No prescription pad. Just a framework, slowly being built, for adults to access psilocybin in a supervised setting.

That was years ago now, and the rollout has been messier and more interesting than anyone predicted. If you're sitting in 2026 wondering whether Oregon's program is actually a path you can walk, or whether it's relevant to your own thinking about a psilocybin retreat, this is the honest version of where things stand and what it means.

What Measure 109 Actually Did (and Didn't Do)

Let's get the basics out of the way. Measure 109 created a state-licensed program for the supervised use of psilocybin by adults. It did not make mushrooms legal to grow in your backyard, sell to your neighbor, or take recreationally. Possession outside the licensed framework is still illegal under Oregon law, though a separate ballot measure decriminalized small personal amounts to the lowest law-enforcement priority.

The companion piece — the one most people miss — is that none of this changes federal law. Psilocybin remains a Schedule I substance at the federal level, which means the DEA still classifies it as having no accepted medical use. The state and the feds are essentially looking past each other on this, which is the same uneasy arrangement that's been propping up state cannabis programs for years.

What you get inside Oregon is a service model. You show up at a licensed service center, you go through a preparation session with a licensed facilitator, you take a measured dose of psilocybin produced by a licensed manufacturer, and you stay there — often for six to eight hours — while a facilitator sits with you. Then there's an integration conversation afterward. It's not therapy in the clinical sense (facilitators aren't required to be therapists), and it's not a free-for-all either.

Why People Are Paying Attention to Psilocybin in the First Place

The research story is what makes all of this more than a policy curiosity. Over the past decade, work out of Johns Hopkins, NYU, and a handful of other institutions has produced some of the most striking mental-health results in modern psychiatry — particularly for people who haven't responded to conventional antidepressants. Studies on treatment-resistant depression, end-of-life anxiety in cancer patients, and tobacco and alcohol addiction have all shown effects that, frankly, would be considered remarkable if they came from a pharmaceutical pill.

A few things stand out in that literature. The effects tend to come from a small number of doses — sometimes just one or two — rather than daily medication. They seem to persist for months. And they appear to work through something psychologically meaningful, not just a chemical lever. People describe sessions that reframe how they relate to grief, fear, or the patterns they've been stuck in for years.

None of this is a guarantee that a psilocybin session will fix what's wrong, and serious researchers are careful to say so. The data is promising; it isn't a finished story. But it's strong enough that ignoring psilocybin's potential, as a category of medicine, has gotten harder to defend.

Is Oregon's Program the Same as a Retreat? Not Quite.

This is where people get confused, and it matters if you're trying to make a real decision. Oregon's service-center model is not a multi-day retreat in the traditional sense. You don't typically stay overnight. You don't typically join a group ceremony with songs and ritual. It's closer to an outpatient session — show up, sit with a facilitator, have your experience, go home (or to a hotel) once you're cleared to leave.

Retreats, by contrast, usually involve several days of preparation, multiple ceremonies, group meals, and structured integration time. They draw on lineages — Mazatec, Amazonian, contemporary therapeutic — that shape how the medicine is offered. Some are run in jurisdictions where psilocybin is legal or unregulated (the Netherlands has long had a workaround using psilocybin truffles; Jamaica has hosted retreats for years). Others operate in the gray zones of various countries.

Each model has trade-offs:

• Oregon service centers: legally sanctioned within the state, transparent pricing, regulated product, but often expensive per session and lighter on the communal/ritual elements.
• International retreats: deeper container, multiple ceremonies, group dynamic, often a lineage-based framework, but variable quality and you're traveling far from home for integration.
• Underground or guide-led sessions: more flexibility, often skilled practitioners, but no legal protection and no consumer oversight.

Which one fits depends on what you're after. Someone working with end-of-life anxiety might want the medicalized, closer-to-home option. Someone exploring chronic depression or a long-standing stuck pattern might want the deeper container of a retreat. Neither is automatically better.

The Cost Question Nobody Wants to Answer Plainly

Here's the part that surprises people. A single supervised psilocybin session in Oregon often runs anywhere from $1,500 to $3,500 once you factor in the preparation meeting, the dosing session, the facilitator's time, the product itself, and integration. Insurance doesn't cover it. That's not the program's fault — building this kind of infrastructure from scratch is expensive — but it has meant that the people who can access psilocybin legally in the U.S. tend to be the people who could already afford a flight to a retreat somewhere else.

Retreats abroad range widely too. A short psilocybin retreat in the Netherlands can run $2,000 to $4,000 including lodging and meals. Longer programs with more ceremonies push higher. The famous Jamaica retreats have charged in the five-figure range for premium experiences. The point is, no path here is cheap, and the legal options haven't yet delivered the affordability that early advocates hoped for.

How to Think About Whether This Is Right for You

If you're reading this because you're considering psilocybin for depression, anxiety, addiction, grief, or just a long stuck feeling that won't shift, a few questions are worth sitting with before you book anything.

1. What are you actually hoping for? Symptom relief, insight, a felt sense of connection, help with a specific behavior — these are different goals and they point toward different containers.
2. Are you on medications that interact? SSRIs, MAOIs, lithium, and several other psychiatric meds interact with psilocybin in ways that matter. Any reputable program will screen for this. If yours doesn't ask, that's a red flag.
3. What's your mental-health history? Psilocybin carries real risk for people with personal or family histories of psychotic disorders. Honest screening protects you.
4. Who's holding the space? Credentials matter, but so does the question of whether the facilitator actually knows what they're doing when something difficult comes up mid-session. Ask. Listen to how they answer.
5. What does integration look like? The session is one day. The work of making sense of it can take months. A program that hands you a flyer and waves goodbye is selling half the medicine.

One thing I'd push back on, gently: the framing that psilocybin is a cure. The research is genuinely exciting, and people do have experiences that change their lives. But the substance is a doorway, not a destination. What you do in the weeks and months after — therapy, lifestyle change, the slow work of putting insights into practice — is where the real shift happens or doesn't.

What's Changed Since Oregon Started

Colorado has since passed its own program with a somewhat different design. Other states have introduced bills, working groups, and pilot programs at various stages. The FDA has continued to grant Breakthrough Therapy designation to psilocybin-assisted treatment for major depression, which signals that the federal landscape is at least slowly moving. Clinical trials have multiplied. Insurance reimbursement is still mostly a fantasy, but there's chatter about pilot programs.

The retreat world has also matured. There are more facilitators with serious training, more lineages openly teaching, more honest conversation about what can go wrong, and — importantly — more public reckoning with bad actors. The early years of this resurgence had a tendency to treat every charismatic guide as enlightened. That's softened into something more discerning, which is good for everyone.

For readers ready to look at specific options, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whether you end up in Oregon, abroad, or simply continue researching for another year, the most important step is the one most people skip: getting clear, before you book anything, on what you're actually hoping the medicine will help you with.